PixarBio Announces 7-Day Neurorelease Pain, And USPTO Patent Filing For “Sprinkle On” 3-Day Neurorelease™ Pain Sterile Powder

CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation announced the expansion of our NeuroRelease™ Pain Platform to include a 7-Day post-surgical pain treatment and a 3-Day sterile powder known as “Sprinkle-On” NeuroRelease™. With recent patent application filings to the USPTO for “Sprinkle On” NeuroRelease™, a sterile powder form to be sprinkled into incisions and wounds, both 7-Day and “Sprinkle-On” products are now covered in the PixarBio USPTO patent applications portfolio.

“NeuroRelease™ represents the holy-grail of pain treatment, and the quality of the KOL’s we signed this summer to our clinical advisory board, speaks volumes to the potential market opportunity and to the clinical impact of NeuroRelease™”

NeuroRelease™ Platform, non-addictive, non-opiate pain platform

NeuroRelease™ is a morphine strength, non-addictive pain treatment for the hospital setting, for the battlefield, or for acute and chronic pain. First product FDA approval for the platform will be for a 14-day post-surgical pain treatment is expected in 2018. A major benefit of NeuroRelease™ is there is no effect on locomotion nerve fibers, so patients can still control their locomotion nerve fibers movements and move around with a morphine strength treatment that is non-addictive. NeuroRelease™ only effects sensory or pain signaling nerve fibers.

“Sprinkle-On” Version of NeuroRelease™

Like Vancomycin, an antibiotic that is sprinkled into incisions and wounds to reduce infection, NeuroRelease™ can be sprinkled into incisions and wounds to provide pain treatment. We envision “Sprinkle On” NeuroRelease™, a 3-day sterile powder that can be used in a range of non-hospital settings such as the battlefield where the current use of morphine leads to immobilized soldiers. Since, NeuroRelease™ does not affect locomotion fibers, soldiers can move themselves to safety. Emergency room trauma is a logical application in the clinic and “Sprinkle On” NeuroRelease™ will be a welcomed new pain treatment option for physicians performing surgery.

Market analysis confirms significant market demand for an incisional or wound pain products. A 3-day “Sprinkle On” pain treatment, is expected to receive FDA approval in 2019. In addition to the “Sprinkle On” application, the versatile 3-day pain treatment is also engineered for use in nerve blocks and soft tissue infiltrations.

PixarBio NeuroRelease™ pain platform also includes 4-8 hour, 3-day, 7-day, 14-day and 90-Day pain treatments all have expected FDA approvals in 2020. NeuroRelease™ is biodegradable, and it’s non-toxic so NeuroRelease™ is the only non-opiate under review at the FDA that can be re-injected to extend treatment timelines. “NeuroRelease™ represents the holy-grail of pain treatment, and the quality of the KOL’s we signed this summer to our clinical advisory board, speaks volumes to the potential market opportunity and to the clinical impact of NeuroRelease™,” said CEO Frank Reynolds.

Last month PixarBio Corporation was awarded the Boston Business Journal’s “2016 Best Places to Work”. The award recognizes PixarBio as one of the region’s best firms, offering the greatest professional opportunities and work environments to innovate; the company is excited to bring “Sprinkle On” NeuroRelease™ to market in 2019.

About PixarBio Corporation
Cofounded by Frank M. Reynolds, MIT’s Dr. Robert S. Langer, Katrin Holzhaus, Dr. Jason Criscione, Haining Dai, Xi Chen, and Dr. Amer Khalil. PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. For more information visit www.pixarbio.com.